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Context: In women with polycystic ovary syndrome (PCOS), 17-hydroxyprogesterone (17-OHP) re-
sponses to gonadotropin stimulation vary from increased to indistinguishable comparedwithnormal controls.
Objective: To determine whether 17-OHP responses to recombinant-human chorionic gonadotropin
(r-hCG) are individually correlated to the size of antral follicles among women with PCOS.
Design, Setting, and Participants: A prospective study conducted in 19 women with PCOS and 20
normal controls at an academic medical center.
Interventions: Blood samples were obtained before and 24 hours after administration of 25 mg of
r-hCG. Ovarian imaging was conducted with three-dimensional pelvic ultrasonography. Each subject
underwent a 2-hour oral glucose tolerance test.
MainOutcomeMeasures:Basal and stimulated levels of 17-OHP, androgens, estradiol, progesterone,
anti-Mullerian hormone (AMH), insulin, glucose, follicle number, and size.
Results: InwomenwithPCOS,meanantral follicle count (AFC)wasgreater than that of controls, although the
size of cohort follicles within individual subjects was not correlated to 17-OHP responses. The numbers of 2- to
3-mmand 3- to 4-mm follicles in PCOSwere significantly greater than in controls, whereas differences between
larger follicles were not observed. Increased AMH in PCOS was correlated to AFC, but not 17-OHP responses.
Insulin sensitivity did not correlate to r-hCG‒stimulated 17-OHP after adjustment for body mass index.
Conclusions: 17-OHP responses to hCG in individuals with PCOS were not correlated to the dis-
tribution of antral follicles. Greater numbers of small antral follicles in women with PCOS than in
controls suggest an extension of accelerated growth from the preantral stage.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
Freeform/Key Words: 17-OHP, follicle, polycystic ovary syndrome
In women with polycystic ovary syndrome (PCOS), excessive androgen production is derived
from ovarian theca cells (TCs), resulting in elevated circulating levels of testosterone (T) and
androstenedione (A4). Mechanisms contributing to androgen overproduction include
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dehydroepiandrosterone sulfate; GC, granulosa cell; GDF-9, growth differentiation factor 9; hCG, human chorionic gonadotropin; P4,
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increased LH secretion, hyperinsulinemia, and increased TC responsiveness to gonadotropin
stimulation. With respect to the latter, we and other investigators have demonstrated ex-
aggerated 17-hydroxyprogesterone (17-OHP) responses to gonadotropin administration in
women with PCOS compared with responses in normal controls [1–5]. However, despite a
significant mean increment of 17-OHP following gonadotropin stimulation among women
withPCOS, individual responses rangedwidely and included some that were indistinguishable
from those of normal women. These results may reflect varying TC sensitivity to gonadotropin
stimulation among women with PCOS. Alternatively, the spectrum of 17-OHP responses to
human chorionic gonadotropin (hCG) may be a direct result of corresponding TC hyperplasia
within individual follicle populations.
Regarding the latter, we have raised the possibility that heterogeneous 17-OHP responses
in women with PCOS may reflect differences in maturational growth of the follicle cohort
among individuals with this disorder [5]. Previous studies showed that the increased follicle
population in PCOS is predominantly composed of small (2 to 5 mm) antral follicles [6, 7].
Although larger follicles (6 to 9 mm) comprise a small percentage of the follicle population in
PCOS, the number of these advanced follicles is similar to that observed in women with
normal ovaries [6]. During normal follicular growth, increasing size is accompanied by
greater TC mass. Correspondingly, in women with PCOS, advanced follicle growth might be
expected to increase TC hyperplasia, which, at least in part, would contribute to greater
ovarian androgen excess. A detailed analysis of the proportion of follicles according to size
among individual womenwith PCOS has not been performed andmay shed light on disparate
17-OHP responses to hCG.
To determine whether the number and size distribution of follicles in women with PCOS
account for varied 17-OHP responsiveness to hCG, we performed a detailed analysis of
ovarian follicle number and corresponding size using three-dimensional ultrasonography
among normal controls and women with PCOS undergoing hCG stimulation.
1. Subjects and Methods
A. Subjects
Nineteen womenwith PCOS and 20 normal womenwith regular menstrual cycles were enrolled
in this study. Women with PCOS and normal subjects were recruited through University of
California, San Diego outpatient clinics and responses to advertisements in the San Diego area.
All women with PCOS were oligomenorrheic or amenorrheic and demonstrated either bio-
chemical (serum T .55 ng/mL) or clinical evidence of androgen excess or clinical evidence of
androgen excess (Ferriman-Gallwey score .8). Women with PCOS demonstrated evidence of
bilaterally enlarged ovaries with more than 12 antral follicles per ovary. Circulating TSH and
prolactin levels were normal and were not significantly different between the two groups. Serum
17-OHP was greater than 2 ng/mL in three women with PCOS. Nonclassical congenital adrenal
hyperplasia was excluded by an ACTH stimulation test. No participant received any hormone
medication or metformin within 2 months of study enrollment. The study was approved by the
Human Research Protection Program at the University of California, San Diego (IRB#140260),
and written informed consent was obtained from each individual prior to participation.
B. Procedures
Subjects were admitted to the Clinical and Translational Research Institute at theUniversity
of California, San Diego on the days of testing. Normal subjects were studied during the
midfollicular phase (cycle days 5 to 8), whereas women with PCOS were studied on a random
day. Each subject received IV administration of recombinant hCG (r-hCG), 25 mg. Blood
samples were collected prior to and 24 hours following r-hCG injection. Each subject also
underwent a 75-g oral glucose tolerance test. Blood was obtained prior to (t = 0) and at t = 15,
30, 60, and 120 minutes following glucose ingestion. Insulin sensitivity was derived from the
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formula described by Matsuda and DeFronzo [8]. For the imaging portion of the study, each
participant underwent transvaginal ultrasonography (Voluson E8 Expert; GE Healthcare,
Chicago, IL) using a 4- to 9-MHz probe (RIC5-9-D Endocavity transducer; GE Healthcare,
Chicago, IL) to obtain three-dimensional imaging of each ovary using the SonoAVC™
software. Assessment of ovarian morphology included the total antral follicle count (AFC) of
both ovaries in each subject as well as the size of each follicle as determined by its diameter in
1-mm increments between 2 and 9 mm. None of the subjects with PCOS experienced recent
ovulation, as evidenced by the absence of recent menstrual bleeding for 2 months before the
study and serum progesterone (P4) level less than 1.0 ng/mL at a baseline sample.
C. Hormone Measurements
Blood was assayed by the Ligand Assay and Analysis Core Laboratory of the University of
Virginia Center for Research in Reproduction. All assays were validated using the following
indices: accuracy, linearity, functional sensitivity (i.e., the lowest concentration with accuracy
to a known standard within 20% and intra-assay coefficient of variation [CV] [1] ,20%),
precision, and correlation to a previous or established method. LH, FSH, insulin, total T, and
P4 levels were measured by chemiluminescence (Immulite 2000; Siemens, Los Angeles, CA);
sensitivities = 0.1 IU/L, 0.1 IU/L, 2.0 uIU/mL, 10 ng/dL, and 0.1 ng/mL; intra-assay CVs =
3.9%, 3.0%, 2.5%, 4.9%, and 4.2%; and interassay CVs = 5.2%, 5.5%, 7.7%, 7.1%, and 5.8%,
respectively [9–13]. 17-OHP, A4, and dehydroepiandrosterone (DHEA) were measured by
ELISA (ALPCO, Salem, NH); sensitivities = 0.15 ng/mL, 0.1 ng/mL, and 0.4 ng/mL; intra-
assay CVs = 6.1%, 4.4%, and 5.7%; and interassay CVs = 7.1%, 8.9%, and 9.7%, respectively
[14–16]. Estradiol (E2) was measured by ELISA (CalBiotech, El Cajon, CA); sensitivity =
10 pg/mL; intra-assay CV = 6.7%; and interassay CV = 9.8% [17]. Anti-Mullerian hormone
(AMH) was measured by ELISA (ANSH, Webster, TX); sensitivity = 0.16 ng/mL; intra-assay
CV = 1.6%; and interassay CV = 6.1% [18, 19]. Glucose was measured by the glucose oxidase
method using the Analox Instrument (Stourbridge, UK); sensitivity = 1.0 mg/dL; intra-assay
CV = 0.6%; and interassay CV = 1.2%.
D. Statistical Analysis
Statistical analysis was performed using JMP program version 13 (SAS Institute, Cary, NC).
Results are presented as means 6 SEM (SE). A value of P , 0.05 was considered statistically
significant. Normality of distribution was assessed by the Shapiro-Wilk W test. In the absence
of normality, datawere appropriately transformed or nonparametric testing (Wilcoxon/Kruskal
Wallis test, Wilcoxon signed rank test) was carried out when appropriate. To analyze dis-
tribution of follicles by percentage of total, follicle counts for each size range were converted to
proportion of overall counts for each individual. Pooled datawere transformed by themethod of
Box and Cox and subjected to ANOVA followed by post hoc testing between specific pairs using
the Student t test for specific differences between groups based on diagnosis.
2. Results
A. Clinical Data
Clinical data for individual women with PCOS and normal women are listed in Table 1. The
mean (6SE) ages for the PCOS and normal groups were 26.3 6 1.1 and 26.9 6 1.3 years,
respectively. The mean body mass index (BMI) of subjects with PCOS was 30.9 6 1.5 kg/m2,
compared with 26.0 6 2.2 kg/m2 in control participants (P = 0.02). The total number of
follicles as well as the number of follicles according to 1-mm increments from 2 to 9 mm in
individual normal women and women with PCOS are also shown in Table 1. In the normal
group, total follicle numbers ranged from 11 to 70, compared with women with PCOS, in
whom the range of follicle numbers was 25 to 132.
doi: 10.1210/js.2018-00339 | Journal of the Endocrine Society | 689
B. Basal Hormone Levels
Basal levels of serum LH, 17-OHP, A4, T, E2, and AMH were significantly higher in women
with PCOS than in the group of normal controls (Table 2). In women with PCOS, FSH was
significantly lower than in controls, whereas circulating levels of DHEA and DHEAS
were similar.
C. Steroid Hormone Responses to r-hCG
Individual 17-OHP responses following r-hCG in both groups are illustrated in Fig. 1. To
account for differences in basal hormone levels, the percentage change from baseline fol-
lowing r-hCG was used to calculate hormone responsiveness. Following administration of
Table 1. Clinical Data for Normal Controls and Women With PCOS
Subject Age (y)
Wt
(kg)
BMI
(kg/m2)
Folla
Total
Folla
2–3 mm
Folla
3–4 mm
Folla
4–5 mm
Folla
5–6 mm
Folla
6–7 mm
Folla
7–8 mm
Folla
8–9 mm
Control
1 27 50.6 21.3 22 2 2 5 8 5 0 0
2 19 66.8 25.8 28 6 3 10 5 1 0 1
3 26 51.2 19.2 23 2 3 7 3 4 3 1
4 32 55.1 21.0 24 6 1 2 3 5 4 1
5 25 64.9 23.0 11 1 3 3 3 0 0 0
6 28 85.0 28.2 60 12 14 12 8 5 2 3
7 34 51.8 20.5 21 5 1 4 2 2 2 2
8 29 55.6 23.1 21 3 3 6 2 3 1 1
9 27 54.4 19.7 16 1 3 5 2 0 2 0
10 27 78.9 29.7 49 7 3 10 7 15 2 2
11 30 59.3 22.2 53 8 10 11 10 8 2 0
12 21 59.9 21.5 39 10 8 8 2 7 1 1
13 31 69.8 29.1 43 10 10 9 6 1 0 1
14 25 52.7 21.1 26 6 2 3 3 4 2 3
15 20 72.6 29.1 70 22 11 22 6 4 2 0
16 20 71.0 24.0 26 4 8 5 2 1 0 1
17 20 50.7 19.9 50 13 5 9 6 4 6 1
18 19 58.8 24.8 33 6 6 8 4 3 2 0
19 28 78.6 27.2 13 2 2 4 1 0 1 0
20 26 71.4 25.0 36 7 5 11 3 1 2 2
PCOS
1 34 49.9 18.7 109 35 34 27 8 0 0 0
2 33 65.7 23.3 90 27 29 19 6 0 0 0
3 29 85.8 32.5 111 10 9 18 22 35 12 2
4 34 84.2 31.0 51 14 10 12 12 0 0 1
5 33 82.4 30.1 25 5 3 2 3 5 2 2
6 33 68.7 26.8 119 34 32 20 15 1 0 0
7 25 76.7 28.6 62 6 6 10 8 22 6 4
8 20 77.3 25.4 92 28 32 21 5 0 0 0
9 35 72.7 26.1 84 17 16 18 26 5 0 0
10 37 83.9 29.7 97 53 23 8 1 0 1 0
11 27 70.6 29.8 80 31 31 13 1 0 0 0
12 23 99.5 36.8 103 27 27 21 17 3 0 0
13 26 69.6 27.9 38 16 10 5 1 0 0 0
14 26 69.2 26.7 132 28 29 46 17 6 0 0
15 29 97.8 32.7 40 7 10 9 8 2 0 0
16 19 99.2 35.0 65 16 17 12 3 3 0 0
17 26 52.2 19.6 58 12 8 16 14 6 0 2
18 28 97.5 35.8 60 17 17 12 9 3 0 1
19 19 61.6 24.4 31 9 11 5 4 2 0 0
aNumber of follicles.
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r-hCG, significant percentage increases in 17-OHP and Twere observed inwomenwith PCOS
compared with normal controls, whereas A4 and DHEA responses between groups were not
different. As noted in Fig. 1, among women with PCOS, individual 17-OHP responses to
r-hCG were highly variable, with many individual responses appearing similar to those of
controls. These findings are consistent with our previously published results as well as those
of other investigators. There was no significant relationship between serum AMH and 17-
OHP responses to r-hCG in contrast to our earlier reported results.
D. Oral Glucose Tolerance Test
During the oral glucose tolerance test, integrated insulin responses (area under the curve)
were higher in women with PCOS than in controls. Correspondingly, insulin sensitivity was
significantly lower in women with PCOS, 6.9 6 0.9, than in normal women, 12.5 6 1.5. In
women with PCOS, 17-OHP responses to hCG were correlated with insulin sensitivity.
However, after adjusting for BMI differences in insulin responses, insulin sensitivity between
groups was no longer observed.
Table 2. Steroid Hormone Levels Prior to and 24 H After r-hCG, 25 mg, in Normal Controls and Women
With PCOS
Hormone Basal 24 H %D Max
17-OHP, ng/mL
Control 0.9 6 0.1 1.6 6 0.1 67%
PCOS 1.4 6 0.1 3.2 6 0.5 140%a
A4, ng/mL
Control 2.2 6 0.1 2.5 6 0.1 17%
PCOS 2.8 6 0.2 3.5 6 0.2 27%
T, ng/mL
Control 14.8 6 1.5 17.3 6 2.2 20%
PCOS 29.7 6 3.8 42.6 6 4.3 97%b
DHEA, ng/mL
Control 9.8 6 1 9.6 6 0.7 8%
PCOS 7.8 6 0.8 10 6 1.7 32%
Data are expressed as mean adjusted 6 SE. To convert to SI units, multiply by the following conversion factor:
17-OHP (3.03); A4 (3.49); T (3.47); DHEA (3.47). %D Max, percent change from basal values.
aP , 0.01.
bP , 0.05.
Figure 1. Individual serum 17-OHP levels prior to and 24 h following administration of
r-hCG, 25 mg IV, in normal controls and women with PCOS.
doi: 10.1210/js.2018-00339 | Journal of the Endocrine Society | 691
E. Ovarian Follicle Morphology
As expected, in women with PCOS the mean total AFC was markedly greater than that of
normal controls (75 6 6 vs 32 6 6; P = 0.001). In addition, the AFC was positively correlated
with serum AMH (P , 0.0001). Analysis of follicles by 1-mm increments revealed signifi-
cantly increased absolutemean numbers of follicles in individual groups of 2 to 3mm through
5 to 6mm in women with PCOS compared with normal controls (Fig. 2). At larger sizes, mean
follicle numbers between groups were not statistically different. Based on the percentage of
total follicles within an individual subject, only 2- to 3-mm and 3- to 4-mm follicles in PCOS
ovaries were significantly greater than those in normal ovaries (Fig. 2). Beyond 4 mm,
differences inmean percentage of follicle number between PCOS and normal ovaries were not
noted. Among individual women with PCOS, the distribution of follicles by absolute number
and by percentage of total was not correlated to 17-OHP responses to hCG. In addition,
associations were not found between androgen responses to hCG and follicle number or
serum AMH.
3. Discussion
The results of this study have confirmed our previous findings that in women with PCOS
mean 17-OHP responses to hCG were significantly greater than those of normal controls,
although individual responses were wide ranging. As expected, the AFCwas higher in women
Figure 2. Mean (6SE) follicle number and mean (6SE) distribution of follicles (percentage
of total follicle number within an individual) according to size in normal controls and women
with PCOS. *, P , 0.05.
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with PCOS than in normal women. However, analysis of follicle distribution within indi-
vidual women with PCOS revealed that 17-OHP responses to hCG were not related to the
distribution of follicles by size. There were greater numbers of small antral follicles in ovaries
of women with PCOS than in ovaries of normal controls. However, beyond 4 mm this dis-
tinction was not evident between groups.
Increased 17-OHP responsiveness to hCG in women with PCOS compared with that of
normal women is consistent with findings reported by others [1–5]. Notably, individual re-
sponses in women with PCOS were highly variable, as some were exaggerated whereas others
were equivalent to those observed in normal women. It was previously reported that increased
17-OHP responses to gonadotropin stimulation were associated with reduced insulin sensi-
tivity comparedwith observations in normalwomen [4]. Itwas proposed that increasing insulin
resistance and greater hyperinsulinemia provided a basis for enhanced TC responsiveness. In
the current study, 17-OHP responses were not correlated to basal insulin levels or insulin
sensitivity after adjustment for BMI. The disparity of BMI between groups as well as limited
numbers of subjects studied precluded comparison of our data with that of Pasquali et al. [4].
There are data suggesting an inherent defect of TC steroidogenesis in women with PCOS
[20–22]. In particular, Gilling-Smith et al. [21] demonstrated that in human TC cultures, LH-
stimulated A4 production per cell was significantly greater in cells obtained from women with
PCOS than in those from normal controls. In a subsequent clinical study, the same authors
examined 17-OHP and A4 responses to hCG stimulation in women with PCOS and normal
women before and 1month after an injection of a long-actingGnRHagonist [22]. After 1month,
reduced gonadotropin secretion and ovarian suppression were evident, as basal 17-OHP and
A4 levels were decreased in both groups. In normal women, there was a corresponding re-
duction of 17-OHP and A4 following hCG stimulation. However, in women with PCOS, the
heightened magnitude of response following hCG was unchanged from pretreatment values.
Whether the high dose of intramuscular hCG—10,000 IU—obscured subtle differences among
individual subjects is unclear. Subsequently, Rosencrantz et al. [23] performed a dose-response
study revealing that maximal A4 and T responses to hCG in women with PCOSwere achieved
at low doses of hCG, whereas minimal responses at comparable doses of hCG were observed in
normal control subjects. Although these data support a primary abnormality of androgen
steroid production in women with PCOS, this concept does not account for the heterogeneous
17-OHP responsiveness exhibited by our subjects.
Alternatively, it has been reported that intraovarian factors may influence TC ste-
roidogenesis. Among members of the tumor growth factor b superfamily, growth differen-
tiation factor 9 (GDF-9) appears to have a vital role in TC development [24]. In GDF-9
knockout mice, the TC compartment failed to develop [25]. Moreover, in this model, GDF-9
was responsible for induction of CYP17 expression and androgen production in TCs of follicles
at the preantral stage [26, 27]. In ovaries from women with PCOS, we showed that GDF-9
mRNA expression was significantly reduced in oocytes of growing and small antral follicles
compared with that observed in normal oocytes [28]. Because lowered GDF-9 mRNA was
evident in nearly all PCOS oocytes, it is unlikely that GDF-9 contributed to variable 17-OHP
responses to hCG.
It was previously reported that certain bone morphogenetic proteins (BMPs) may exert
inhibitory effects on TC androgen production [26, 29]. In bovine TCs, BMP-4, BMP-6, and
BMP-7 decreased basal and LH-stimulated androgen accumulation primarily through
suppression of CYP17mRNA expression [14]. The role of these BMPs was underscored by the
ability of chordin and gremlin to antagonize the stimulation of androgen production [20].
Notably, within the ovary, gremlin and chordin are derived from granulosa cells as is BMP-6,
whereas BMP-4 and BMP-7 are from TCs. These findings suggest that interactions between
these BMPs and their antagonists involve complex paracrine or autocrine mechanisms yet to
be precisely defined. Consequently, at this time the role of BMPs in TC androgen production
in PCOS cannot be determined.
There is little question that other granulosa cell factors may impact TC androgen pro-
duction. Both in vitro and in vivo studies performed in animals and humans have indicated
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that FSHmay stimulate ovarian androgen production. Early studies showed that the addition
of inhibin to TC culture resulted in increased basal as well LH-stimulated androgen responses
[30–34]. In women with PCOS, we reported significant increases in ovarian androgen pro-
duction following FSH administration compared with that in normal women [35]. The in-
cremental androgen responses exhibited by women with PCOS accompanied by similar
significant increments in FSH-stimulated inhibin-B levels. To determine whether inhibin
mediates TCCYP17mRNA expression, ovarian TCswere examined in the presence or absence
of granulosa cells treated with FSH, inhibin, inhibin antibody, or b-glycan antibody [36].
CYP17 mRNA expression was dose-dependently increased by FSH, which suggests that
paracrine factors from granulosa cells (GCs) mediated CYP17 mRNA expression. Antibodies
against inhibin and b-glycan prevented FSH stimulation of CYP17 mRNA expression.
However, inhibin alone did not increaseCYP17mRNA level to the same extent. Although these
findings suggest that inhibinmay participate in regulating TCCYP17mRNAexpression, other
paracrine factors produced by FSH-stimulated granulosa cells appear to be involved.
RegardingwomenwithPCOS inwhom17-OHP responses were indistinguishable from those
of normal women, an obvious explanation is not apparent. In the report by Pasquali et al. [4]
exaggerated 17-OHP responses to GnRH agonists in women with PCOS were attributed to
hyperinsulinemia as reflected by significant elevations of plasma insulin during an oral glucose
tolerance test. However, in women with PCOS with normal 17-OHP responses, insulin levels
during glucose loadingwere also significantly greater than in controls. Iba~nez et al. [3] examined
hCG-stimulated 17-OHP levels in 23 women with PCOS and found that in 15 individuals
responses were above the 95th percentile of 28 control subjects. Normal 17-OHP responsiveness
observed in the remaining eight women with PCOS was not addressed. In an early study by
Barnes et al.,womenwith PCOS exhibited significantly increased 17-OHP responses to aGnRH
agonist [20]. Maximal responses did not overlap with those of normal controls, although the
number of women with PCOS studied was limited to eight. In a previous publication of dis-
parate 17-OHP responses to hCG in women with PCOS, we considered whether differences in
follicle cohort populations among individuals might account for our findings [5].
Previous histological studies of ovaries from women with PCOS have demonstrated
predominant numbers of preantral and early antral follicles that reflect maturational arrest
at the midstage of follicle development [37–39]. Our ultrasonographic findings are consistent
with these observations. However, follicle arrest does not appear to be complete cessation of
progressive growth, as advanced antral follicles exist and spontaneous ovulation is known to
occur in these women. Despite these considerations, results of the current study revealed that
in individual womenwith PCOS, 17-OHP and androgen responses to hCGwere not correlated
to the size distribution of antral follicles. Thus, greater 17-OHP responses do not appear to be
attributable to a cohort of larger antral follicles with corresponding greater TC mass. In
addition, the distribution pattern of follicles in PCOS ovaries suggests that accelerated
follicle growth is a characteristic feature of small antral follicle development in this disorder.
This increased rate of growth may represent an extension of preantral follicle advance-
ment as previously reported [38, 39]. In an earlier study by Webber et al. [38], the accu-
mulation of growing follicles in PCOS was greater than that in normal controls. Of note, the
proportionate increase of growing follicles in PCOSwas accompanied by a reciprocal decrease
in the proportion of primordial follicles. In a subsequent study by Maciel et al. [39], there
was a stockpiling of primary and secondary follicles in ovaries from women with PCOS that
was significantly greater than those in normal ovaries. Although there was no difference in
the number of primordial follicles between groups, the percentage of growing follicles relative
to the number of primordial follicles was nearly twofold higher in PCOS than in normal
ovaries. Thus, both studies suggested an accelerated transition of primordial to growing
preantral follicle development in PCOS. Interestingly, initiation of primordial follicle growth
has been observed in 2-day-old mouse ovaries treated with androgen. It was shown that both
T and DHT stimulated an increase of phosphatidylinositol 3-kinase/protein kinase B (AKT),
which resulted in activation of Forkhead box (Foxo)-3a [40]. This led to translocation of Foxo
protein from the nucleus to the cytoplasm, allowing for transitional primordial follicle
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growth. These findings are consistent with studies conducted in nonhuman primates and
sheep in which T treatment during gestation resulted in enhanced preantral follicle growth
[41, 42]. In particular, prenatal exposure to T in sheep resulted in a proportionate increase of
primary follicles and a reduction of primordial follicles [43].
In our study, we noted that beyond 4 mm a difference in the number of follicles between
groups was no longer present, implying a slowing of follicle growth in PCOS. Whether this
relative decline in the rate of growth by PCOS follicles is due to an inhibitory process or a lack
of continued stimulation is unknown. Nevertheless, at this early stage of antral growth,
PCOS follicles appear to be quite vital, as shown by Das et al. [44]. Examination of follicles (4
to 5mm) obtained from unstimulated follicles revealed lower rates of apoptosis and increased
proliferation in GCs from women with PCOS compared with those from normal women.
Moreover, GCs from PCOS follicles exhibited lower expression of apoptotic effector caspase-3
and increased amounts of inhibitor of apoptosis protein-2 than those of normal GCs.
In follicles larger than 4 to 5mm, the impact of androgen on development and health is less
clear. Using an encapsulated in vitro ovarian follicle growth system, the effect of androgen on
multilayered secondary follicles was examined during progressive growth in mice [45].
Treatment with DHT resulted in advanced growth and accelerated preantral to antral follicle
development. Prolonged exposure to DHT had no effect on steroidogenesis on days 2 and 4 of
culture, but it decreased endogenous androgen synthesis on day 6. In addition, low-dose DHT
enhanced follicle growth and survival, whereas these effects were reversed or not apparent
with increasing doses.
In women with PCOS, it has been well regarded that arrest of follicle growth occurs at the
midantral stage of development. According to the results of previously cited studies, together
with our imaging data, it appears that this process may be initiated at or just beyond 4 to
5 mm. Of note, with increasing size, the follicle number as percentage of total follicle count in
PCOS actually was less than that of controls, although the number of advanced-size follicles
was low in both groups.
There was considerable overlap in total follicle numbers among individual normal controls
and women with PCOS. This is not necessarily surprising because polycystic ovary mor-
phology has been reported to be at least as high as 50% in women with normal ovulation [46,
47]. Moreover, it seems unlikely that similar follicle morphology as determined by ultra-
sonography reflects comparable follicle function between normal women and women with
PCOS. To date, assessment of polycystic ovary morphology on a functional basis in normal
women and those with PCOS has not been explored in detail. As a result, this consideration
represents a limitation of our study. Studies attempting to address this issue are currently
under way.
Similar to our previously published results, serum AMH levels were increased in women
with PCOS compared with normal controls [5, 48]. However, unlike our earlier findings, in
the current study AMH levels were not inversely correlated with 17-OHP responses to hCG.
These results differ from those recently published by Rosenfield et al. [49] in that AMH levels
in women with PCOS were positively correlated to 17-OHP responses to a GnRH agonist.
Interestingly, among 48 women with PCOS and ovarian hyperandrogenism, 77% exhibited
high responses, whereas in a much larger study of 148 women with PCOS, excessive 17-OHP
responses to a GnRH agonist were found in 50% [4]. However, AMHwas not measured in the
latter study. By comparison, the limited numbers of subjects in both our early study and the
current study preclude any interpretation of the relationship between AMH levels and 17-
OHP responses. Currently, another study involving far greater numbers of normal women
and subjects with PCOS is being conducted and includes evaluation of follicle populations.
Another shortcoming of our study was that subjects were not matched for weight or BMI. As a
result, the positive correlation between 17-OHP response to hCG and reduced insulin
sensitivity was lost after adjustment for BMI.
In summary, the results of this study have shown that the spectrum of 17-OHP responses
to hCG inwomenwith PCOSwas not correlated to the size of antral follicles among individual
subjects. Notably, the distribution of follicles by size in women with PCOS suggests an
doi: 10.1210/js.2018-00339 | Journal of the Endocrine Society | 695
extension of accelerated growth from preantral stage to early antral stage development.
Thereafter, follicle growth is slowed, most likely reflecting the initiation of follicle arrest in
this disorder.
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